China Biotech Evolving at Lightning Speed

Stifel

Research

19 Pages

Stifel’s Tim Opler shares impressions from a June trip to China, where biotech is moving fast on engineering, cost and cycle times while first in class innovation becomes more common. Roughly half of large pharma’s sizable licensing deals in 2026 have been sourced from China, and portfolio R&D deals with Chinese partners are a growing trend.

Key Takeaways

Half From China: Chinese counterparties account for 50% of large pharma licensing deals with $50 million or more upfront in 2026, up from 0% in 2019.
Upfront Dollars Shift: 68% of all dollars and equity paid in biopharma license deals in 2026 went to Chinese counterparties, nearly double the 35% in 2025.
Portfolio R&D Deals: Four portfolio R&D deals with Chinese firms, led by AstraZeneca and CSPC, brought $3.2 billion in upfront payments this year.

Join our newsletter to have all of this content + Exclusive Newsletter Bonus Content delivered to your inbox every week

Related Content

Scroll to Top